Download PDF
Journal of Pediatric Neurology 2021; 19(05): 352-354
DOI: 10.1055/s-0040-1721131
Case Report

Hydrocephalus in Spinal Muscular Atrophy: A Case Report and Review of the Literature

Jeetendra P. Sah 
1   Department of Pediatric Neurology, SUNY Downstate Health Sciences University, Brooklyn, New York, United States
,
Aaron W. Abrams
1   Department of Pediatric Neurology, SUNY Downstate Health Sciences University, Brooklyn, New York, United States
,
Geetha Chari
1   Department of Pediatric Neurology, SUNY Downstate Health Sciences University, Brooklyn, New York, United States
,
Craig Linden
2   Department of Radiology, SUNY Downstate Health Sciences University, Brooklyn, New York, United States
,
Yaacov Anziska
3   Department of Neurology, SUNY Downstate Health Sciences University, Brooklyn, New York, United States
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

In this article, we reported a case of spinal muscular atrophy (SMA) type I noted to have tetraventricular hydrocephalus with Blake's pouch cyst at 8 months of age following intrathecal nusinersen therapy. The association of hydrocephalus with SMA is rarely reported in the literature. Development of hydrocephalus after intrathecal nusinersen therapy is also reported in some cases, but a cause–effect relationship is not yet established. The aim of this study was to describe the clinical characteristics of a patient with SMA type I and hydrocephalus, to review similar cases reported in the literature, and to explore the relationship between nusinersen therapy and development of hydrocephalus. The clinical presentation and radiographic findings of the patient are described and a comprehensive review of the literature was conducted. The adverse effect of communicating hydrocephalus related to nusinersen therapy is being reported and the authors suggest carefully monitoring for features of hydrocephalus developing during the course of nusinersen therapy.

Keywords

spinal muscular atrophy - hydrocephalus - nusinersen - Blake's pouch cyst

Authors' Contributions

J.P.S. designed and conceptualized study, reviewed and drafted the manuscript for intellectual content. A.W.A. contributed to design of the study, and revised the manuscript for intellectual content. G.C. contributed to conception and designing, and revised the manuscript for intellectual content. C.L. contributed to design, and revised the manuscript for intellectual content. Y.A. contributed in conceptualization and designing, and also revised the manuscript for intellectual content.




Publication History

Received: 06 September 2020

Accepted: 19 October 2020

Article published online:
19 November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Sardone V, Zhou H, Muntoni F, Ferlini A, Falzarano MS. Antisense oligonucleotide-based therapy for Neuromuscular disease. Molecules 2017; 22 (04) 563
    CrossrefPubMedSearch in Google Scholar
  • 2 Farrar MA, Park SB, Vucic S. et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol 2017; 81 (03) 355-368
    CrossrefPubMedSearch in Google Scholar
  • 3 D'Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis 2011; 6 (01) 71
    CrossrefPubMedSearch in Google Scholar
  • 4 Hoy SM. Nusinersen: first global approval. Drugs 2017; 77 (04) 473-479
    CrossrefPubMedSearch in Google Scholar
  • 5 Michelson D, Ciafaloni E, Ashwal S. et al. Evidence in focus: nusinersen use in spinal muscular atrophy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 91 (20) 923-933
    CrossrefPubMedSearch in Google Scholar
  • 6 Biogen Idec Ireland. Spinraza (nusinersen): communicating hydrocephalus not related to meningitis or bleeding reported. [Internet]. 2018 . Available at: https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information-spinraza-(nusinersen).pdf?sfvrsn=0. Accessed Nov 5, 2020
    PubMedSearch in Google Scholar
  • 7 Shohoud SA, Azab WA, Alsheikh TM, Hegazy RM. Blake's pouch cyst and Werdnig-Hoffmann disease: report of a new association and review of the literature. Surg Neurol Int 2014; 5 (Suppl. 04) S282-S288
    CrossrefPubMedSearch in Google Scholar
  • 8 Mendonça RH, Rocha AJ, Lozano-Arango A. et al. Severe brain involvement in 5q spinal muscular atrophy type 0. Ann Neurol 2019; 86 (03) 458-462
    CrossrefPubMedSearch in Google Scholar
  • 9 Tozawa T, Kasai T, Tatebe H. et al. Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: a case report focusing on the neurofilament light chain in cerebrospinal fluid. Brain Dev 2020; 42 (03) 311-314
    CrossrefPubMedSearch in Google Scholar
  • 10 Tortori-Donati P, Fondelli MP, Rossi A, Carini S. Cystic malformations of the posterior cranial fossa originating from a defect of the posterior membranous area. Mega cisterna magna and persisting Blake's pouch: two separate entities. Childs Nerv Syst 1996; 12 (06) 303-308
    CrossrefPubMedSearch in Google Scholar
  • 11 Takanashi J-I, Takase N. Reader response: evidence in focus: nusinersen use in spinal muscular atrophy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2019; 93 (10) 464
    PubMedSearch in Google Scholar
  • 12 Falsaperla R, Wenzel A, Raudino G. et al. Intrathecal administration of nusinersen in patients with SMA1: too little is known. Neurol Case Rep. 2019; 2 (02) 1012
    PubMedSearch in Google Scholar
  • 13 Hirono S, Ito D, Murai H. et al. Postnatal development of Blake's pouch cyst: a case report and new insight for its pathogenesis. Childs Nerv Syst 2014; 30 (10) 1767-1771
    CrossrefPubMedSearch in Google Scholar